USE OF CANNABIDIOL (CBD) IN GENERALIZED ANXIETY DISORDER: CURRENT EVIDENCE AND THERAPEUTIC PERSPECTIVES

Authors

  • Bianca Suellen Ferreira
  • João Eugênio Henrique Heidemann e Silva
  • Guilherme Ângelo Faria Rickli
  • Valéria Caprioli Breda
  • Ana Cláudia Queiroz Mota Simas
  • Valéria Goulart Viana
  • Anésia Bezerra da Fonsêca
  • Júlio Cézar Reis Protásio
  • Geovani Teixeira Pinto
  • Thays Almeida de Oliveira
  • Harrison Oliveira Santiago
  • Mariáh França Guimarães Meirelles de Paula
  • Mayara Cardoso
  • Wanderson Carlos Santos Agra
  • Bruno Henrique Nakagawa
  • Pabllo Adelino Estevam Barbosa
  • Celso Gabriel Donati de Mendonça Duarte
  • João Gonçalves Simões Filho
  • Brenda Maria Leite Ferreira
  • Daniel Gomes Fialho
  • Gabriel Alves Pereira Isac

Keywords:

Cannabidiol, Generalized Anxiety Disorder, Mental Health, Medicinal Therapy, Cannabis sativa

Abstract

This study aims to review the current scientific evidence regarding the use of cannabidiol (CBD) in the treatment of Generalized Anxiety Disorder (GAD). CBD, one of the main phytocannabinoids derived from Cannabis sativa, exhibits a consistent anxiolytic potential without inducing significant psychoactive effects, distinguishing it from tetrahydrocannabinol (THC). Preclinical and clinical evidence indicates that CBD modulates the endocannabinoid system and serotonergic receptors, promoting anxiety reduction in both experimental contexts and clinical practice. Although the results are promising, important methodological limitations remain, including small sample sizes, heterogeneous protocols, and the lack of standardized dosages. Current findings suggest that CBD may represent a safe and effective therapeutic alternative, particularly for patients with inadequate response or intolerance to conventional treatments. However, further high-quality randomized clinical trials are needed to strengthen the scientific evidence and support the development of clear clinical guidelines for the rational use of CBD in the management of anxiety.

DOI:https://doi.org/10.56238/sevened2025.031-030 

Downloads

Published

2025-09-16

Issue

Contemporary Dialogues in Health Sciences

Section

Articles

License

Copyright (c) 2025 Bianca Suellen Ferreira, João Eugênio Henrique Heidemann e Silva, Guilherme Ângelo Faria Rickli, Valéria Caprioli Breda, Ana Cláudia Queiroz Mota Simas, Valéria Goulart Viana, Anésia Bezerra da Fonsêca, Júlio Cézar Reis Protásio, Geovani Teixeira Pinto, Thays Almeida de Oliveira, Harrison Oliveira Santiago, Mariáh França Guimarães Meirelles de Paula, Mayara Cardoso, Wanderson Carlos Santos Agra, Bruno Henrique Nakagawa, Pabllo Adelino Estevam Barbosa, Celso Gabriel Donati de Mendonça Duarte, João Gonçalves Simões Filho, Brenda Maria Leite Ferreira, Daniel Gomes Fialho, Gabriel Alves Pereira Isac

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Ferreira, B. S. ., Heidemann e Silva, J. E. H. ., Rickli, G. Ângelo F., Breda, V. C., Simas, A. C. Q. M., Viana, V. G. ., da Fonsêca, A. B. ., Protásio, J. C. R. ., Pinto, G. T., de Oliveira, T. A., Santiago, H. O., de Paula, M. F. G. M. ., Cardoso, M. ., Agra, W. C. S. ., Nakagawa, B. H., Barbosa, P. A. E. ., de Mendonça Duarte, C. G. D. ., Simões Filho, J. G., Ferreira, B. M. L. ., … Isac, G. A. P. . (2025). USE OF CANNABIDIOL (CBD) IN GENERALIZED ANXIETY DISORDER: CURRENT EVIDENCE AND THERAPEUTIC PERSPECTIVES. Seven Editora, 466-485. https://sevenpubl.com.br/editora/article/view/8063